Tekla Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$18.3M Hold
147,779
0.72% 39
2023
Q1
$21.6M Sell
147,779
-35,003
-19% -$5.18M 0.82% 35
2022
Q4
$29.1M Hold
182,782
1.1% 28
2022
Q3
$24.4M Buy
182,782
+14,883
+9% +$2.26M 1% 31
2022
Q2
$26.2M Buy
167,899
+27,426
+20% +$4.22M 1.03% 28
2022
Q1
$21.9M Buy
140,473
+23,158
+20% +$3.36M 0.77% 35
2021
Q4
$14.9M Buy
117,315
+3,256
+3% +$428K 0.48% 51
2021
Q3
$14.9M Buy
114,059
+46,603
+69% +$7.04M 0.48% 54
2021
Q2
$12M Hold
67,456
0.39% 66
2021
Q1
$11.1M Hold
67,456
0.38% 70
2020
Q4
$11.1M Hold
67,456
0.39% 75
2020
Q3
$9.62M Hold
67,456
0.36% 64
2020
Q2
$7.44M Hold
67,456
0.28% 77
2020
Q1
$6.73M Sell
67,456
-18,217
-21% -$2.36M 0.3% 66
2019
Q4
$12.8M Buy
85,673
+10,737
+14% +$1.46M 0.48% 44
2019
Q3
$9.6M Buy
74,936
+7,465
+11% +$1M 0.42% 57
2019
Q2
$9.62M Hold
67,471
0.39% 59
2019
Q1
$9.64M Sell
67,471
-47,716
-41% -$6.22M 0.39% 53
2018
Q4
$14.3M Buy
115,187
+4,735
+4% +$702K 0.61% 38
2018
Q3
$18.6M Hold
110,452
0.67% 38
2018
Q2
$19M Sell
110,452
-12,030
-10% -$1.97M 0.72% 36
2018
Q1
$18.5M Buy
122,482
+24,061
+24% +$3.53M 0.72% 34
2017
Q4
$13.3M Sell
98,421
-175,495
-64% -$24.3M 0.51% 43
2017
Q3
$40.1M Hold
273,916
1.43% 19
2017
Q2
$42.6M Sell
273,916
-57,495
-17% -$8.79M 1.58% 18
2017
Q1
$48.1M Hold
331,411
1.86% 17
2016
Q4
$36.1M Hold
331,411
1.54% 20
2016
Q3
$40.3M Buy
331,411
+174,960
+112% +$23.6M 1.55% 19
2016
Q2
$22.1M Sell
156,451
-22,640
-13% -$3.34M 0.9% 29
2016
Q1
$23.4M Buy
+179,091
New +$22.3M 0.99% 25
2015
Q3
Sell
-120,357
Closed -$21.2M 166
2015
Q2
$21.2M Sell
120,357
-384
-0.3% -$69K 0.77% 30
2015
Q1
$20.9M Sell
120,741
-80,600
-40% -$13.8M 0.83% 30
2014
Q4
$33M Buy
201,341
+28,100
+16% +$4.66M 1.54% 17
2014
Q3
$27.8M Buy
173,241
+77,284
+81% +$11.9M 1.3% 21
2014
Q2
$14.1M Buy
+95,957
New +$13.3M 1.29% 20

Other funds holding JAZZ

Tekla Capital Management's JAZZ Position: Q2 2023 in Review

Tekla Capital Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2023 at 147,779 shares worth $18.3M. The position accounts for 0.72% of the portfolio, ranked #39.

Tekla Capital Management first reported a position in JAZZ in Q2 2014 and has held it in 35 quarters since. The position peaked at $48.1M in Q1 2017. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

  • Tekla Capital Management held 147,779 shares of Jazz Pharmaceuticals worth $18.3M as of Q2 2023.
  • Tekla Capital Management left its Jazz Pharmaceuticals share count unchanged in Q2 2023.
  • Jazz Pharmaceuticals made up 0.72% of Tekla Capital Management's portfolio in Q2 2023, its #39 holding.
  • Tekla Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2014 and has held it in 35 quarters since.
  • Tekla Capital Management's Jazz Pharmaceuticals position peaked at $48.1M in Q1 2017.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.